Clinical study of zoledronic acid combined with radiotherapy for bone metastases malignancy
- VernacularTitle:唑来膦酸联合放疗治疗骨转移癌效果观察
- Author:
Weihong ZHENG
;
Xu LI
;
Zhi CHEN
- Publication Type:Journal Article
- Keywords:
Metastatic bone tumour;
Zoledronic acid;
Radiotherapy
- From:
Clinical Medicine of China
2008;24(12):1262-1264
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy of zoledronic acid combined with radiotherapy for metastatic bone tumours. Methods Eighty patients with metastatic bone tumour by meta were randomly derided into two groups study group(n=40), and the eantrol group (n=40). The study group received 4 mg zoledronic acid infusion for 15 minutes combined with radiotherapy (DT 30Gy/10f/2w) ,control group was only treated with radiotherapy. The primary effective parameters were pain scores, quality of life, KPS scores and pain relief rates. The vital signs, bi-ochemical and hematological parameters were determined. Results The overall response rates of study group and control group were 97.5% and 72.5% ,respectively(P<0.05). The overall response rate of movement capacity im-provement was 87.5 % in the study group and 65.0% in the control group(P<0.05). There was statistical signifi-cance of QOL and KPS in two groups (P<0.01). An adverse event of mild systemic skeletal pain was recorded after pamidronate infusion and completely reversed after 8 hours. Conclusion Zoledronic acid combined with radiothera-py is effective and safe for treating malignant tumour with mestastatic bone tumours. It is a better way to treat meta-static bone tumors at present.
